SCHEMBL15524290

SCHEMBL15524290

COC(=O)CC(Cc1ccccc1)c1nc(Nc2ccc(N3CCN(C(=O)O)CC3)cc2)ncc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 7/20 0.47
▸ CDK2 P24941 3/20 0.46
▸ CCNK O75909 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CCND3 P30281 1/20 0.46
▸ CDK9 P50750 1/20 0.46
▸ CDK6 Q00534 1/20 0.46
▸ STAT6 P42226 4/20 0.44
▸ ALK Q9UM73 1/20 0.43
▸ CDK4 P11802 4/20 0.42
▸ CCND1 P24385 4/20 0.42
▸ CCNE1 P24864 2/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ CCNB1 P14635 1/20 0.42
▸ MAP3K7 O43318 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAP2K1 Q02750 1/20 0.42
▸ BRD4 O60885 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524227 0.91 CCND3 (0.58) SYKCDK2CCNKCCNA2CCND3
SCHEMBL15524121 0.91 SYK (0.51) SYKCDK2CCNKCCNA2CCND3
SCHEMBL14576325 0.89 PTK2 (0.48) SYKCDK2CCNKCCNA2CCND3
SCHEMBL15524767 0.84 FLT4 (0.43) CCND3STAT6CDK4CCND1JAK3
SCHEMBL15524080 0.83 CCND3 (0.58) SYKCDK2CCNKCCNA2CCND3
SCHEMBL15524676 0.82 IGF1R (0.46) CDK2CDK9CDK1JAK2JAK1
SCHEMBL12478821 0.81 CCND3 (0.52) SYKCDK2CCNKCCNA2CCND3
SCHEMBL14576997 0.79 PTK2 (0.51) SYKCDK4CCND1JAK2
SCHEMBL15524018 0.79 PTK2 (0.44) CDK2CCNA2CDK9JAK2JAK3
SCHEMBL12478740 0.79 PTK2 (0.53) SYKSTAT6CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266864-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-02-23 — — US disclosed
US-20150225377-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2015-08-13 — — US disclosed
US-20140080798-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225377-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR SYK 126/4885CDK2 133/4885CCNK 208/4885
US-20140080798-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR SYK 171/4885CDK2 144/4885CCNK 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback